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Background: Pulse oximetry has become an important tool in evaluating, and monitoring
pulmonary diseases, but the knowledge about arterial oxygen saturation (SpO2) values in
a general population is limited. The aim of this study was to describe the distribution of low
pulse oximetry values in a general adult population and their association with certain predic-
tors.
Methods: A cross-sectional population based survey was performed in Tromsø, Norway, in 2007
e2008. Valid SpO2 and pre-bronchodilator spirometry was recorded in 6317 participants aged
38e87 years (57% women). Resting SpO2 95% was defined as an abnormal value. Predictors of
SpO2 95% with p < 0.05 were entered into a binary multivariable logistic regression.
Results: The prevalence of SpO2 95% was 6.3%. The strongest predictors in the logistic regres-
sion were increased body mass index (BMI) (OR of BMI 35 Z 6.2, CI(4.2, 9.2)), and reduced
forced expiratory volume in 1 s (FEV1) % predicted (OR of FEV1% predicted <50 Z 4.1,
CI(2.5, 6.7)), followed by increased age, male gender, and smoking (p < 0.001). Other signif-
icant predictors were elevated C-reactive protein (CRP) (p < 0.005), former smoking, breath-
lessness and elevated hemoglobin (p < 0.01).
Conclusion: Airflow limitation and other known signs of pulmonary diseases were, as expected,
strongly associated with decreased oxygen saturation. Obesity was also a strong predictor of
low SpO2, and should be included among possible explanations when low SpO2 values are
encountered.
ª 2012 Elsevier Ltd. All rights reserved.626828; fax: þ47 77628261.
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Pulse oximeters are cheap and widely used non-invasive
devices for estimating arterial oxyhemoglobin saturation
(SaO2), denoted by SpO2. Causes of decreased arterial
oxygen saturation are hypoventilation, ventilation e
perfusion mismatch, right to left shunts, reduced diffusion
capacity and reduced oxygen partial pressure in inspired
air. There are a broad range of applications for pulse oxi-
metry, including emergency medicine, intensive care,
surgery, and sleep and respiratory medicine.
There is limited knowledge about the distribution of
resting SpO2 values in a general adult population. One study
applied pulse oximetry in the selection of patients for
spirometry in order to diagnose chronic obstructive
pulmonary disease (COPD), but was not found useful.1
There is no clear cut-off point for abnormal oxygen satu-
ration, but SpO2 95% is used in some studies.2 Resting SpO2
95% has been found to predict oxygen desaturation during
sleep3 and during exercise4 in COPD patients. SpO2 95%
has also been identified as a risk factor for postoperative
pulmonary complications.5 The cut-off value of 92% has
been used when screening for respiratory failure in COPD.6
Lower SpO2 in COPD has been identified to be a risk factor
for exacerbations7 and mortality.8
The aim of this study was to determine the prevalence of
low pulse oximetry values in an adult general population,
and to identify independent predictors of low values.Methods
Participants
Tromsø is the largest city in northern Norway with approxi-
mately 68 000 inhabitants, situated at sea level. The Tromsø
Studywas initiated in 1974.9 FromOctober 2007 till December
2008 the Tromsø study was conducted for the sixth time. The
invited population consisted of four groups: Subjects who
took part in the special study in the Tromsø 4 survey, a 10%
random sample of subjects aged 30e39 years, all individuals
aged 40e42 and 60e87 years, and a 40% random sample of
subjects aged 43e59 years. A total of 19762 men and women
were invited. The attendance rate was 65.7% (12984), lower
among men (62.9%) and in the youngest (30e45 years) and
oldest (80e87 years) age groups (for more information www.
tromsostudy.com). Participants of the first examination were
invited to a second more extended medical examination if
they had taken part in the special study in Tromsø 4, all in the
age groups 50e62 and 75e84 years, and a 20% random sample
of subjects aged 63e74 years. 7958 were invited. The atten-
dance rate was 91.8% (7307). From this last group 6477 had
their SpO2 and 6438 their spirometry recorded, 6427 had both
recordings. Absence of staff, technical problems and people
leaving before the examinations started, are reasons for not
having examined the whole group.
Questionnaires
A Questionnaire was mailed together with the invitation
including questions about general health, diseases andsmoking habits. Participants who reported to suffer from
angina pectoris, myocardial infarction, cerebral stroke or
atrial fibrillation were classified as “self-reported cardio-
vascular disease”. People who attended the study received
another questionnaire which they were asked to complete
and return immediately or by mail. In this second ques-
tionnaire they were asked about dyspnoea, cough and
sputum. Finally, those attending the spirometry session had
to complete a brief computerized questionnaire including
questions about recent symptoms of airway infection and
use of regular medication for asthma or COPD taken on the
day of the examination. The questionnaires are available on
the Tromsø Study website (www.tromsostudy.com).
Examinations
At the first examination, the participants underwent
a limited medical screening including height, weight and
pulse. Height and weight were measured standing, wearing
light clothing without shoes. Body mass index (BMI) (kg/m2)
was calculated. Blood was drawn for hemoglobin
measurement. Cut-offs for raised value was based on the
reference values used at the University Hospital of Northern
Norway, Tromsø. For women the upper normal limit was
16.0 g/dL and for men 17.0 g/dL.
Pulse oximetry and spirometry were part of the
extended examination. SpO2 values were measured with
a digital handheld pulse oximeter (Onyx II emodel 9550)
(Nonin Medical, Inc., Plymouth, MN, USA). The participants
rested at least 15 min before examination. The best of
three measurements was recorded. The manufacture’s
testing has shown that only values between 70 and 100 are
accurate to within 2 digits, and values below 70% were
regarded as invalid.
Spirometry was carried out with the use of SensorMedics
Vmax 20c Encore (VIASYS Healthcare Respiratory Technol-
ogies, Yorba Linda, CA, USA). American Thoracic Society
(ATS)/European Respiratory Society (ERS) criteria were
followed.10 Norwegian reference values for pre-
bronchodilator spirometry were used11 since reversibility
tests were not performed. Calibration of the instrument
was performed every morning and at the machine’s
demand. Three trained technicians shared conducting the
spirometry. The test was performed with subjects sitting,
using a nose clip. At least three exhalations were required.
The difference between best and second best forced
expiratory volume in 1 s (FEV1) and forced vital capacity
(FVC) should not exceed 5% and 150 ml. Current drug
therapy was not interrupted before the test.
On the same day, as part of the second examination,
blood was drawn for C-reactive protein (CRP) analysis and
measured with a high-sensitivity immuno-turbidimetric
assay as previously described.12
Statistical analysis
Characteristics of the participants where compared by
gender, and the differences explored by using Man-
neWhitney U rank and Chi-square test.
In the main analyses the SpO2 values were divided
into reduced value, 95%, and normal value >95%. The
Predictors of oxygen saturation 95% in a cross-sectional population based survey 1553frequency of reduced SpO2 were analyzed by gender, age,
smoking habit, spirometry, BMI, hemoglobin, CRP, self-
reported health and diseases, pulmonary symptoms, and
medication. Continuous variables (age, BMI, FEV1, and
CRP) were categorized and the statistical significance of
differences was analyzed by Chi-square test. Predictors of
SpO2 95% with a statistical significance of <5% were
entered into a multivariable binary logistic regression and
excluded by backward stepwise elimination. Only predic-
tors with p < 0.05 were kept in the final model. The
multivariable analysis was also done without categorizing
the continuous variables. The SPSS, version 18.0 (SPSS Inc,
Chicago, IL, USA) was used.
The Regional Committee for Medical and Health
Research Ethics in North Norway approved the Tromsø 6
survey. All the participants gave written informed
consent.Table 1 Characteristics of the 6317 study subjects by gender.
Al
Total numbers 63
Age (years)
Self reported diseases
Asthmab 6
COPD 3
Cardiovascular diseasesb 11
Hypertensionc 20
Diabetesd 3
Self reported general healthc
Good/excellent 38
Neither good nor bad 20
Bad/very bad 3
Smoking historyb
Never smoking 21
Former smoking 29
Smoking 11
Lung symptoms
Breathless when walking uphill or rapidly on level groundb 30
Breathless when walking calmly, washing and
dressing, or at restb
4
Daily cough with sputum some periods of the yearc 6
Symptoms of airway infection last 7 days 7
Medication
Regular use and medication for
asthma or COPD taken on the day of the examination
4
FEV1% predicted
a
FVC% predicteda
Body Mass Index (kg/m2)a
Heart rate (beat/min)a
Hemoglobin (g/dL)a
C-reactive protein (mg/L)
SpO2 (%)
a
Data are presented as n (%) or mean  SD, unless otherwise indicate
COPD: chronic obstructive pulmonary disease. FEV1: forced expiratory
CRP: C-reactive protein. SpO2: arterial oxygen saturation as measure
a Significant difference between men and women, ManneWhitney t
b Significant difference between men and woman, Chi-square test,
c Significant difference between men and women, Chi-square test,
d Significant difference between men and women, Chi-square test,Results
A total of 6427 had their SpO2 and spirometry recorded.
Participants with SpO2 <70% were excluded (8 partici-
pants). Inadequate spirometry results were excluded -
a total of 102. Valid results for both SpO2 and spirometry
were obtained in 6317 participants, 3600 women (57%) and
2717 men (43%). Summary of the participants’ character-
istics are shown in Table 1. Mean age for the participants
was 63.6 years, range 38e87 years. There were significant
more women than men with self reported asthma and
hypertension, whereas men more frequently reported
cardiovascular diseases. Women reported worse general
health than men. More women than men were current
smokers, whereas previous smoking was more frequently
reported by men. Among the previous and current smokersl Women Men
17 (100) 3600 (57) 2717 (43)
63.6 (9.2) 63.6 (9.2) 63.7 (9.0)
38 (10.1) 413 (11.5) 225 (8.3)
30 (5.2) 202 (5.6) 128 (4.7)
35 (18.0) 488 (13.6) 647 (23.8)
18 (31.9) 1207 (33.5) 811 (29.8)
57 (5.7) 184 (5.1) 173 (6.4)
93 (62.2) 2167 (60.9) 1726 (64.9)
21 (32.3) 1179 (33.2) 842 (31.2)
42 (5.5) 210 (5.9) 132 (4.9)
66 (34.3) 1396 (38.8) 770 (28.3)
22 (46.3) 1454 (40.4) 1468 (54.0)
40 (18.0) 689 (19.1) 451 (16.6)
16 (47.7) 1805 (50.1) 1211 (44.6)
10 (6.5) 268 (7.4) 142 (5.2)
07 (9.6) 322 (8.9) 285 (10.5)
75 (12.3) 435 (12.1) 340 (12.5)
09 (6.5) 250 (6.9) 159 (5.9)
91.5 16.9 93.1 17.0 89.4 16.6
99.5 15.2 100.9 15.5 97.6 14.6
27.1 4.2 26.8 4.6 27.4 3.7
65.5 10.6 66.4 10.2 64.5 11.0
14.2 1.2 13.6 1.0 14.9 1.0
2.84 6.6 2.62 4.5 3.13 8.6
97.5 1.5 97.7 1.4 97.2 1.6
d.
volume in 1 s. FVC: forced vital capacity. BMI: body mass index.
d by pulse oximetry.
est, p < 0.001.
p < 0.001.
p < 0.005.
p < 0.05.
Figure 1 Frequency (%) of arterial oxygen saturation (SpO2)
95% by different level of forced expiratory volume in 1 s
(FEV1) % predicted.
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rettes pr day) were 20.1 among men and 14.8 among
women. However, due to missing data, pack years could
only be calculated in 80.1% of smokers/former smokers,
and this variable was not included in the further analyses.
More women than men reported breathlessness, whereas
more men reported daily cough with sputum. Men had
significantly lower mean FEV1% predicted and higher BMI
than women.
Mean SpO2 for this population was 97.5% (median 98%),
range 72e100%. Men had significant lower SpO2. SpO2 95%
was found in 400 participants (6.3%). Univariate analysis
comparing the frequency of SpO2 95% by the variables in
Table 1 (after categorizing the continuous variables)
showed that all the variables were significant predictors.
There was an increasing frequency of SpO2 95% by
decreasing levels of FEV1% predicted (Fig. 1). The
frequency (%) of SpO2 95% also increased significantly by
increasing levels of BMI, independent of whether FEV1%
predicted was below 80 or not (Fig. 2). Particularly high
frequency of SpO2 95% was found with heart rate >100
beat/min (19.4%) and when the hemoglobin value exceeded
upper limit of normal (19.8%) (Table 2, online version only).
Breathlessness decreased by increasing SpO2 (Fig. 3). We
did not find strong interactions between the predictors, and
interactions were not included in the multivariable anal-
ysis. Fig. 4 shows that the differences between the
predictors persist when higher or lower cut-off levels of
SpO2 than 95% are used.
The results from the multivariable logistic regression
with categorized independent variables are presented in
Table 3. In this analysis 88 of the 6317 were not included
because of missing values in one or more of the variables.
The most important predictors for SpO2 95% were BMI
35 kg/m2 and FEV1<50% predicted, with Odd Ratios of 6.2
and 4.1, respectively. The Nagelkerke Square index of the
model was 0.11. Similar results with FEV1% predicted and
BMI as the strongest predictors were found when the
continuous variables of age, BMI, FEV1% predicted and CRP
were used, and the Nagelkerke Square index was somewhat
higher, 0.14.
Only 30 participants had SpO2 92% (0.5%). By multi-
variable logistic regression with SpO2 92% as outcome
variable, age 80 years, breathlessness (when walking
calmly, washing, dressing, or at rest, see Fig. 3), increased
hemoglobin level, and FEV1<50% predicted, but not BMI,
were found to be significant predictors.Figure 2 Frequency (%) of arterial oxygen saturation (SpO2)
95% by different levels of body mass index (BMI). Different
curves are shown for forced expiratory volume in 1 s (FEV1) %
predicted <80 and 80.Discussion
In this first screening of oxygen saturation in a general
population, the prevalence of SpO2 95% was 6.3%. The
most important predictors of this low oxygen saturation
were decreased FEV1% predicted and increased BMI.
The association between oxygen saturation and FEV1 is
known from studies on COPD, especially when FEV1% pre-
dicted <50.13 In a review study from Franciosi et al.14 they
found that arterial oxygen tension (PaO2) was one of the
parameters that correlated best with FEV1 staging in COPD.
In another study of stable COPD patients with mild to
severe obstruction they found SpO2 92% in 6.3% of thegroup, in 19.4% during acute exacerbations, and in 24.5%
when increased dyspnoea was reported.15 In this study the
strongest predictor of SpO2 92% was FEV1% predicted <50,
a cut-off value often used when COPD patients are evalu-
ated for hypoxia with arterial blood gases.16
Table 2 Frequency of SpO2 95% by subject characteristics
among 6317 study participants.
Total SpO2 95% p-value
n (%)
All 6317 400 (6.3)
Gender
Women 3600 177 (4.9) <0.001
Men 2717 223 (8.2)
Age
<65 years 3672 190 (5.2) <0.001
65 years 2645 210 (7.9)
Self-reported diseases
Asthma 638 68 (10.7) <0.001
COPD 330 51 (15.5) <0.001
Cardiovascular disease 1135 106 (8.3) <0.001
Hypertension 357 32 (9.3) <0.001
Diabetes 2018 167 (9.0) <0.05
Self-reported general health
Good/excellent 3893 191 (4.9) <0.001a
Neither good nor bad 2021 159 (7.9)
Bad/very bad 342 44 (12.9)
Smoking history
Never smoking 2166 91 (4.2) <0.001
Former smoking 2922 210 (7.2)
Smoking 1140 95 (8.3)
Lung symptoms
Breathless when walking
uphill or rapidly on level
ground
3016 251 (8.3) <0.001
Breathless when walking
calmly, washing or dressing,
or at rest
410 54 (13.2) <0.001
Daily cough with sputum
some periods of the year
607 70 (11.5) <0.001
Symptoms of airway
infection the last 7 days
775 65 (8.4) <0.05
Medication
Regular use and medication
for asthma or COPD taken
on the day of the examination
409 57 (13.9) <0.001
FEV1% predicted
<50 107 29 (27.1) <0.001
50e80 1260 127 (10.1)
80 4950 244 (4.9)
BMI (kg/m2)
<25 2072 73 (3.5) <0.001
25e35 3952 269 (6.8)
35 293 58 (19.8)
Heart rate (beat/min)
100 36 7 (19.4) 0.001
80 649 60 (9.2) 0.001
Hemoglobin (g/dL)
>upper limit of normal 81 16 (19.8) <0.001
CRP(mg/L)
5 675 83 (12.3) <0.001
The frequency of SpO2 by certain characteristics is compared
with the frequency in the absence of the same characteristics.
SpO2: arterial oxygen saturation as measured by pulse oxi-
metry; COPD: chronic obstructive pulmonary disease; FEV1:
forced expiratory volume in 1 s; BMI: body mass index; CRP:
C-reactive protein.
a Chi-square test for trend.
Predictors of oxygen saturation 95% in a cross-sectional population based survey 1555Obesity (BMI 30 kg/m2) has previously been found to be
associated with reduced arterial oxygen saturation,17
though most former studies have focused on morbid
obesity (BMI 40 kg/m2). In obstructive sleep apnoea (OSA)
and obesity hypoventilation syndrome (OHS), reduced
resting oxygen saturation has been found, especially in
severe cases.18,19 Obesity may also be associated with
reduced lung volumes.20 Other measures than BMI, such as
Fat Mass Index (FMI)/Fat-Free Mass Index (FFMI) has been
used when COPD patients have been studied and waist-to-
hip ratio has been applied in studies on obesity and hypo-
ventilation.17 We might have found an even stronger asso-
ciation between obesity and SpO2 using other measures
than BMI.
Male gender was associated with decreased oxygen
saturation. In other studies there have been varying results.
In studies determining reference values for arterial blood
gases no gender difference was found in one study21 and
higher values in elderly men than in elderly women in
another.22 Screening awaken asymptomatic adults,
however, showed that lower SpO2 was associated with male
gender.23 In COPD patients’ one study showed higher SpO2
in women,24 but insignificant differences between the
genders have been shown in others.25 In obese, men have
showed lower oxygen saturation than women.17 The effect
of male gender might have been reduced by including the
waist-to-hip ratio in the analysis, since one of the expla-
nations of a higher oxygen saturation in obese women than
in obese men, is that they have less abdominal obesity, and
abdominal obesity is associated with reduced gas
exchange.17 Cardiovascular diseases were more frequent in
men and, although not significant in multivariable analyses,
might have influenced on the gender effect.
Age 65 years were associated with SpO2 95% and age
80 years with SpO292%. Reference values for blood gases
andoxyhemoglobin saturations dropwith increasingage.21,22
In this study there was a negative linearity between mean
SpO2 and age, as expected due to aging processes and added
exposures, and dichotomizing the age variable somewhat
reduced the effect in the multivariable model.
Smoking is associated with lower oxygen saturation
through the development of emphysema, COPD and chronic
bronchitis.26 Smoking was associated with decreased SpO2.
Former smoking also showed a weak, but significant asso-
ciation. In a study from the US23 they did not find this
association, but the population was younger and without
pulmonary symptoms. The predictive value of former
smoking in the multivariable model is probably related to
the limitation of spirometry in expressing the severity of
the smoking related damage to the lungs.26,27
CRP was a predictor of SpO2 95%. This has also been
seen in COPD patients.28 Increased CRP has been associated
with an unfavourable prognosis in COPD29 and overall
mortality in a general population.30 Obesity, OSA and OHS
are associated with increased CRP.31,32 The association
between SpO2 and mean CRP was linear. A different cut off
value could have been used, for instance 3 mg/L [29, 30],
but 5 mg/L was a stronger predictor.
Self-reported dyspnoea was also an independent
predictor of SpO2 95%, and breathlessness on low grade
activity (when walking calmly, washing, or dressing) pre-
dicted SpO2 92%. Such an association has previously been
Figure 3 Frequency (%) of breathlessness by different levels
of arterial oxygen saturation (SpO2). Different curves are
shown for breathlessness when walking uphill or rapidly on
level ground and breathlessness when walking calmly, washing
and dressing, or at rest.
Figure 4 Frequency (%) of arterial oxygen saturation (SpO2)
by age >75 years, forced expiratory volume in 1 s (FEV1) % <60,
body mass index (BMI) 35 kg/m2, current smoking, C-reactive
protein (CRP) 5 mg/L and none of the characteristics above.
1556 M.L. Vold et al.found in COPD patients.15 The degree of dyspnoea has often
not been associated with the degree of desaturation during
exercise.33 In this study more women than men experi-
enced breathlessness even though women had higher SpO2
values. This has also previously been demonstrated in COPD
studies.34,35
Regular use of medication for COPD or asthma, taken on
the examination day, was associated with low oxygen
saturation. This variable was a stronger predictor than self-
reported asthma or COPD, which did not attain statistical
significance in the model. This was probably related to
a more a severe disease in the subgroup of asthma and
COPD patients who took medicine regularly.
Including more independent variables might have
increased the explanatory power of our model, for instance
history of heart failure or serum pro-brain natriuretic
peptide (ProBNP).
The high participation rate is a major strength of this
study, reducing the risk of selection bias. However, in the
oldest age group (80e90 years) the participation rate was
relatively low. Severe co-morbidity may have been a reason
for non-participation in the survey, and the effect of age
could thus have been somewhat underestimated. In all of
the Tromsø surveys non-attendants have tended to be
younger, single, and the proportion of men to be high-
er(except the first survey where only men were included).9
Lower mortality has been found in subjects who were
consistent attendees in Tromsø 2e4 compared to the ones
invited to all three, but only attending Tromsø 4.9 In this
study the frequency of non-attendants was higher in thosewho never had participated in the previous Tromsø study
surveys. We might have examined a somewhat more
healthy population with higher pulse oximetry values than
would be found in the general population.
When using questionnaires recall bias and misclassifica-
tion errors are a concern. People especially tend to
misclassify when asked about smoking history. A stronger
association between smoking and low oxygen saturation
may have been shown, if valid data on pack-years with no
missing values could have been included.
We chose to use logistic regression in our analyses and
not linear regression. We did so since the prevalence of
values outside the normal limits was low and since it is
difficult to assess the importance of the variation of SpO2
within the narrow normal range. Categorizing the possible
predictors and displaying the results as Odds Ratios made it
easier to compare the importance of the various predictors.
Using continuous variables did not offer a much better
model, with Nagelkerke R Square increasing from 0.11 to
0.14. The interaction between FEV1 % predicted and BMI
had little impact when using categorized data.
Measuring oxygen saturation by pulse oximetry has
important limitations, especially when measuring values in
the lower limits.36 Heavy smokers may have their saturation
overestimated, since high carboxyhemoglobin levels may
give overestimation of true SpO2. To validate the device
used, future studies could include analysis of blood gas in
a subsample or comparison with another device.
Table 3 Factors associated with arterial oxygen saturation
(SpO2) 95% in the multivariable logistic regression.
OR 95% CI p-value
Gender man 1.6 (1.3e2.0) <0.001
Age 65 years 1.5 (1.2e1.9) <0.001
Smoking history
Former smoking 1.4 (1.1e1.8) <0.01
Smoking 1.8 (1.3e2.5) <0.001
Lung symptoms
Breathless when
walking uphill or
rapidly on level ground
1.4 (1.1e1.7) <0.01
Medication
Regular use and medication
for asthma or COPD taken
on the day of the examination
1.5 (1.1e2.1) <0.05
FEV1% predicted
<50 4.1 (2.5e6.7) <0.001
50e80 1.6 (1.3e2.0) <0.001
BMI( kg/m2)
25e35 1.8 (1.4e2.4) <0.001
35 6.2 (4.2e9.2) <0.001
Hemoglobin(g/dL) >upper limit 2.3 (1.3e4.2) <0.01
CRP(C-reactive protein - mg/L) 5 1.5 (1.1e2.0) <0.005
Nagelkerke R square for the model 0.11. OR: odds ratio. CI:
confidence interval. SpO2: arterial oxygen saturation as
measured by pulse oximetry. COPD: chronic obstructive
pulmonary disease. FEV1: forced expiratory volume in 1 s. BMI:
body mass index. CRP: C-reactive protein.
Predictors of oxygen saturation 95% in a cross-sectional population based survey 1557Conclusions
Airflow limitation and other known signs of pulmonary
diseases were, as expected, strongly associated with
decreased oxygen saturation in this study. Obesity was also
a strong predictor of low SpO2. Pulse oximetry is safe and
easy to perform, and due to the widespread use of the test,
all sources of reduced measures should be recognized.
Obesity should certainly be included among possible
explanations when low SpO2 values are encountered.Conflict of interest statement
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